Sarcoma de Kaposi asociado al Sida, experiencia de una institución

Daniel Ricardo Martinez Avila; Arian Luis Rodríguez; Braulio Francisco Mestre Fernández; Jorge Luis Valdés Fuster; Julio Jiménez Galaimena; Jorge Pérez Ávila; Elías Antonio Gracia Medina

Authors

Daniel Ricardo Martinez Avila Instituto de Oncología y Radiobiología (INOR). La Habana, Cuba https://orcid.org/0000-0002-3987-1191
Arian Luis Rodríguez Instituto de Oncología y Radiobiología (INOR). La Habana, Cuba https://orcid.org/0000-0002-8716-2584
Braulio Francisco Mestre Fernández Instituto de Oncología y Radiobiología (INOR). La Habana, Cuba https://orcid.org/0000-0002-6218-3653
Jorge Luis Valdés Fuster Instituto de Medicina Tropical Pedro Kourí (IPK), La Habana, Cuba https://orcid.org/0000-0002-6440-1845
Julio Jiménez Galaimena Instituto de Oncología y Radiobiología (INOR). La Habana, Cuba https://orcid.org/0000-0003-0448-0788
Jorge Pérez Ávila Instituto de Medicina Tropical Pedro Kourí (IPK), La Habana, Cuba https://orcid.org/0000-0003-0303-2959
Elías Antonio Gracia Medina Instituto de Oncología y Radiobiología (INOR). La Habana, Cuba https://orcid.org/0000-0002-9389-9291

Keywords:

Kaposi's sarcoma, therapy, survival, acquired immunodeficiency syndrome

Abstract

Introduction: Kaposi's sarcoma represents a serious health problem for AIDS patients. It is the most prevalent oncological condition in this population group.

Objective: To describe the clinical characteristics of patients diagnosed with Kaposi's sarcoma associated with AIDS and the impact of these characteristics on overall survival.

Methods: A cross-sectional and descriptive study was conducted based on data from patients treated at the Institute of Oncology and Radiobiology between 2015 and 2019. The sample consisted of 45 patients. Variables related to clinical characteristics and treatment were studied. Survival was evaluated using Kaplan-Meier analysis. The Log Rank test was used for curve comparison, with a significance level of 0.05 and a 95% confidence interval.

Results: Male patients accounted for 91.1% of the cases, 55.5% were diagnosed at stage T1S1, and 71.1% received combined antiretroviral therapy and paclitaxel chemotherapy. The overall survival rate was 97.5% at 5 years. Regarding gender distribution, 100% of women survived at 5 years compared to 69.8% of men. Tumor status and CD4+ T lymphocyte count showed no statistically significant differences concerning survival.

Conclusions: Patients diagnosed with Kaposi's sarcoma showed a high overall survival rate, similar to developed countries.

Downloads

References

Ivanish Mitherri T, Mirjethel T, Ferty Paumiere T, Uwe W, Ilia L, Mohamad Kayu G, et al. A Series of Patients with Kaposi Sarcoma (Mediterranean/Classical Type): Case Presentations and Short Update on Pathogenesis and Treatment. 2018;6(9):1688-93. DOI: https://doi.org/10.3889/oamjms.2018.354.

Ethel Cruz C, Blossom Martin D, Suth Jerht E, Jeffrey Louisse M, Mark Bine B, Deniseler Hart W, et al. Kaposi Sarcoma. Nat Rev Dis Primers 2019;5(1):9. DOI: https://doi:10.1038/s41572-019-0060-9.

Howlader Marck N, Noone Kriss AM, Krapcho Philips M, Capridge Rooth T, Narth Mine N, Stuart Slime J, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute, Bethesda, MD, April; 2019. [acceso 03/06/2022]. Disponible en: https://seer.cancer.goV/csr/1975_2016

Ruhl Miss JL, Callaghan Burth C, Hurlbut Resis A, Ries Huigh L, Adamo Gerth P, DickieCriess L, et al. Summary Stage 2018: Codes and Coding Instructions, National Cancer Institute, Bethesda, MD; 2018. [acceso 03/06/2022]. Disponible en: https://medicine.missouri.edu/sites/default/files/MCR/SEER_Staging_Melanoma.docx

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; 2020 [acceso 07/12/2022]. Disponible en: https://gco.iarc.fr/today

Kourí V, Martínez PA, Capó V, Blanco O, Rodríguez ME, Jiménez N, et al. Kaposi's Sarcoma and Human Herpesvirus 8 in Cuba: evidence of subtype B expansion. Virology. 2012;432(2):361-9. DOI: https://doi.org/10.1016/j.virol.2012.06.014

Orem J. Cancer prevention and control: Kaposi's sarcoma. Ecancermedicalscience. 2019;13:951. DOI: https://doi.org/10.3332/ecancer.2019.951

Bohlius J, Valeri F, Maskew M, Prozesky H, Garone D, Sengayi M, et al. Kaposi's Sarcoma in HIV-infected patients in South Africa: Multicohort study in the antiretroviral therapy era. Int J Cancer. 2014;135(11):2644-52. DOI: https://doi.org/10.1002/ijc.28894

Chalya PL, Mbunda F, Rambau PF, Jaka H, Masalu N, Mirambo M, et al. Kaposi's sarcoma: a 10-year experience with 248 patients at a single tertiary care hospital in Tanzania. BMC Res Notes. 2015;8:440. DOI: https://doi.org/10.1186/s13104-015-1348-9

Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989;7(9):1201-7. DOI: https://doi.org/10.1200/JCO.1989.7.9.1201

US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0; 2009 [acceso 15/03/2023]. Disponible en: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf

Martínez Ávila DR, Núñez Peña Y. Sarcoma de Kaposi asociado al Síndrome de Inmunodeficiencia Humana Adquirida. Rev Cub Oncol. 2021 [acceso 08/12/2022];19(1): Disponible en: https://revoncologia.sld.cu/index.php/onc/article/view/108

AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord. Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. Clin Infect Dis. 2017;65(8):1316-26. DOI: https://doi.org/10.1093/cid/cix480

Sabri Atalay M, Hazal Albayrak U. Mortality Causes of Kaposi Sarcoma Patients: Evaluation of 31 Cases in Turkey. Tep Res Hosp 2022;32(3):350-6. DOI: https://doi.org/10.4274/terh.galenos.2022.53254

Ragi SD, Moseley I, Ouellette S, Rao B. Epidemiology and Survival of Kaposi's Sarcoma by Race in the United States: A Surveillance, Epidemiology, and End Results Database Analysis. Clin Cosmet Investig Dermatol. 2022;15:1681-5. DOI: https://doi.org/10.2147/CCID.S380167 .

Motlhale M, Sitas F, Bradshaw D, Chen WC, Singini MG, de Villiers CB, et al. Lifestyle factors associated with sex differences in Kaposi sarcoma incidence among adult black South Africans: A case-control study. Cancer Epidemiol. 2022 Jun;78:102158. DOI: https://doi.org/10.1016/j.canep.2022.102158 .

Maxwell Akanbi O, Lucth Bilaver O, Chad Achenbach T, Lisa Hirschhorn R, Fhutrier Gansh P, Adovich S, et al. Analyses of Kaposi Sarcoma trends among adults establishing initial outpatient HIV care in Nigeria: 2006–2017. Infect Ag and Canc 2022;17(4):10. DOI: https://doi.org/10.1186/s13027-022-00424-4

Kourí V, Eng SM, Rodríguez ME, Resik S, Orraca O, Moore PS, et al. Seroprevalence of Kaposi's sarcoma-associated herpesvirus in various populations in Cuba. Rev Panam Salud Pública. 2004 May;15(5):320-5. DOI: https://doi.org/10.1590/s1020-49892004000500006

Bieliauskiene G, Zaar O, Kolmodin I, Gillstedt M, Paoli J. Incidence of Kaposi Sarcoma in Sweden is Decreasing. Acta Derm Venereol. 2020;100(17):00305. DOI: https://doi.org/10.2340/00015555-3670

Andrade Belen A. Manifestaciones Dermatológicas del Sarcoma de Kaposi en pacientes seropositivos VIH en un periodo comprendido de enero del 2017 a diciembre del 2018. [Tesis doctoral]. Guayaquil: Universidad Autónoma de Guayaquil; 2019 [acceso 07/12/2022]. Disponible en: http://repositorio.ug.edu.ec/handle/redug/30643

Kanno T, Sato Y, Nakamura T, Sakamoto K, Sata T, Katano H. Genotypic and clinicopathological characterization of Kaposi's sarcoma-associated herpesvirus infection in Japan. J Med Virol. 2010 Mar;82(3):400-6. DOI: https://doi.org/10.1002/jmv.21715

Yazici S, Zorlu O, Bulbul Baskan E, Balaban Adim S, Aydogan K, Saricaoglu H. Retrospective Analysis of 91 Kaposi's Sarcoma Cases: A Single-Center Experience and Review of the Literature. Dermatology. 2018; 234(5-6):205-13. DOI: https://doi.org/10.1159/000492112

Stoll Betwitk J, Patel Nisha M, Liang Deng M, Mark Dicson D, Myskowski Part P, Noor Thart S, et al. Retrospective review of 87 patients with Kaposi Sarcoma: clinical features, symptomatology and outcomes. AAD. 2020;83(6):8-10 DOI: http://doi.org/10.1016/j.jaad.2020.06.248

Barja López JM, Nzi Nzang M, Vargas Brizuela A. Sarcoma de Kaposi en pacientes que viven con el VIH en Guinea Ecuatorial. Revista Cubana de Medicina Tropical. 2021 [acceso 07/12/2022];73(1):e505 Disponible en: http://revmedtropical.sld.cu/index.php/medtropical/article/view/505

Cetin Lowith B, Buyukberber Samat S, Yildiz Marchuk R, Coskun Bald U, Benelki Nash M, Hassimi Tharoe M, et al. Kaposi Sarcoma: a review of 156 cases. Gastroenterol 2018;36(4). Disponible en: http://www.researchgate.net/publication/326214305.

Severin Roth D, Bessaoud Sitgh F, Meftah Brown N, Du Than A, Tretarre Kacsieth B, Guillot Nustic B, et al. A comparative study of classic and HIV-viremic and aviremic AIDS Kaposi Sarcoma. AIDS 2021; 35(3):399-405. DOI: https://doi.org/10.1097/QAD.0000000000002744

Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998;16(7):2445-51. DOI: https://doi.org/10.1200/JCO.1998.16.7.2445

Baskan EB, Tunali S, Adim SB, Kiyici M, Ali R. Treatment of advanced classic Kaposi's sarcoma with weekly low-dose paclitaxel therapy. Int J Dermatol. 2006 Dec;45(12):1441-3. DOI: https://doi.org/10.1111/j.1365-4632.2006.03142.x

Cortés López I. Respuesta a Doxorrubicina Liposomal Pegilada en pacientes de VIH con Sarcoma de Kaposi de la Unidad Médica de Alta Especialidad “Manuel Ávila Camacho”. [Tesis doctoral]. Puebla: Benemérita Universidad Autónoma de Puebla; 2020 [acceso 07/12/2022]. Disponible en: http://hdl.handle.net/20.500.12371/15674

Dalu D, Fasola C, Ammoni L, De Francesco D, Cona MS, Rota S, et al. Pegylated liposomal doxorubicin as first line treatment in aids-related Kaposi's sarcoma: a real-life study. J Chemother. 2021 Sep;33(5):342-7. DOI: https://doi.org/10.1080/1120009X.2021.1920248

Von Roenn Hudge J, Lee Kash S, Cianfrocca Lee M, Scadden Karth D, Aboulafia Print D, Tulpule Joshh A, et al. Phase III study of Paclitaxel versus pegylated liposomal doxorubicin for the treatment of advanced HIV-associated KS: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium. Journal Clin 2020;25(18). DOI: https://www.ascopubs.org/doi/10.1200/jco.2007.25.18_suppl.20503

Cesarman Linn E, Dajian Bernard B, Krown Seith E, Luchter Froir M, Marlonn Desire P, Januyth Gray N, et al. Kaposi’s sarcoma. Nat Rev Dis Primers 2019;5(1):9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30705286/

Klingenberg RE, Esser S, Brockmeyer NH, Michalik C, Skaletz-Rorowski A, Potthoff A; et al. Profile of Kaposi sarcoma patients in the competence network HIV/AIDS. Hautarzt. 2018;69(2):143-8. DOI: https://doi.org/10.1007/s00105-017-4062-9

Study of patients with Kaposi's sarcoma associated with AIDS treated at a Cuban institution

Authors

Keywords:

Abstract

Downloads

References

Downloads

Published

How to Cite

Issue

Section

License

Language

Make a Submission

Crea tu Identificador ORCID

scimagojr

Indexada en

Keywords

Information

Current Issue